Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Entrectinib→

Entrectinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1108743-60-7
Molecular formula
C31H34F2N6O2
Molecular weight
560.64 g/mol
Drug class
TRK/ROS1/ALK tyrosine kinase inhibitortargeted antineoplastic
Mechanism of action
Inhibits TRKA, TRKB and TRKC, ROS1 and ALK kinase activity, suppressing oncogenic signalling in tumours driven by NTRK gene fusions or ROS1 rearrangements.
Indications / reported uses
  • Treatment of adults and paediatric patients with solid tumours harbouring an NTRK gene fusion, when disease is metastatic or surgery is likely to cause severe morbidity and there is no satisfactory alternative therapy or progression following treatment
  • Treatment of adults with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) under the applicable product label

Sources: US DailyMed — ROZLYTREK (entrectinib) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Entrectinib Environmental Risk Assessment (ERA) (the Entrectinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.